GSK improves guidance as it adapts to life in slimmed down form

UK pharma major GSK (LSE: GSK) has presented its first set of financial results since it spun off its consumer health division Haleon earlier this month.

The London-based drugmaker has raised its full-year revenue and profit guidance in presenting the figures, now predicting sales to grow between 6% and 8% in 2022, up from its prior forecast of 5% to 7%.

"New capacity and flexibility for GSK to invest in growth"GSK’s new guidance for adjusted operating profit growth is 13% to 15%, above its previous forecast of 12% to 14%.